Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases

被引：0

作者：

Maria Fasshauer

Michael Borte

Michaela Bitzenhofer

Christine Pausch

David Pittrow

Michelle Park

André Gladiator

Peter Jandus

机构：

[1] Hospital St. Georg,Hospital for Children and Adolescents

[2] Academic Teaching Hospital of the University of Leipzig,ImmunoDeficiencyCenter Leipzig (IDCL)

[3] Hospital St. Georg,Division of Allergology and Clinical Immunology, Department of Pneumology

[4] Academic Teaching Hospital of the University of Leipzig,Institute for Clinical Pharmacology

[5] University Hospital Berne (Inselspital Bern),Division of Clinical Immunology and Allergy, Department of Medicine

[6] GWT-TUD GmbH,undefined

[7] Innovation Centre Real World Evidence,undefined

[8] Technical University,undefined

[9] Takeda Development Center Americas,undefined

[10] Inc.,undefined

[11] Takeda Pharmaceuticals International AG,undefined

[12] University Hospital and Medical Faculty,undefined

来源：

Advances in Therapy | 2023年 / 40卷

关键词：

Antibody deficiency syndromes; Ig20Gly; Immunoglobulin replacement therapy; Inborn errors of immunity; Observational; Primary immunodeficiency diseases; SCIG; Subcutaneous immunoglobulin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：5168 / 5187

页数：19

共 50 条

[41] How the concept of real-world use affects patient safety
Department of Biomedical Engineering, Texas A and M University, College Station, TX, United States
不详
不详
Biomed. Instrum. Technol., 2006, 4 (283-285):
[42] The use of real-world data to address questions of patient safety
Yates, Mark
Bechman, Katie
Galloway, James
RHEUMATOLOGY, 2020, 59 (01) : 26 - 30
[43] Safety and Efficacy of Home-Based Subcutaneous Immunoglobulin G in Elderly Patients with Primary Immunodeficiency Diseases
Stein, Mark R.
Koterba, Alan
Rodden, Linda
Berger, Melvin
POSTGRADUATE MEDICINE, 2011, 123 (05) : 186 - 193
[44] REAL-WORLD PEDIATRIC EXPERIENCE WITH HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN (IGHY) INFUSION PARAMETERS
Gruenemeier, P.
Ernst, C.
White, C.
Duff, K.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 117 (05) : S98 - S98
[45] Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world, single-centre experience
Ma, Zechen
Johnson, Dylan
Gniadecki, Robert
Ritchie, Bruce
Keeling, Stephanie
Tervaert, Jan Willem Cohen
Osman, Mohammed
RHEUMATOLOGY, 2023, 63 (08) : 2118 - 2122
[46] Efficacy and Safety of Hizentra®, a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency
Michael Borte
Malgorzata Pac
Margit Serban
Teresa Gonzalez-Quevedo
Bodo Grimbacher
Stephen Jolles
Othmar Zenker
Jutta Neufang-Hueber
Bernd Belohradsky
Journal of Clinical Immunology, 2011, 31 : 752 - 761
[47] Efficacy and Safety of Hizentra®, a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency
Borte, Michael
Pac, Malgorzata
Serban, Margit
Gonzalez-Quevedo, Teresa
Grimbacher, Bodo
Jolles, Stephen
Zenker, Othmar
Neufang-Hueber, Jutta
Belohradsky, Bernd
JOURNAL OF CLINICAL IMMUNOLOGY, 2011, 31 (05) : 752 - 761
[48] Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
Kobrynski, Lisa
BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 277 - 287
[49] LONG-TERM SAFETY OF FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN: INSIGHTS FROM A POSTAUTHORIZATION SAFETY STUDY IN PRIMARY IMMUNODEFICIENCY DISEASES
Rubinstein, Arye
Patel, Niraj
Wedner, H. James
Wasserman, Richard
Gupta, Sudhir
Fielhauer, Katharina
Chavan, Shailesh
Yel, Leman
MUSCLE & NERVE, 2021, 64 : S62 - S62
[50] SAFETY/TOLERABILITY OF HUMAN IMMUNE GLOBULIN SUBCUTANEOUS, 20% IN PEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES
Paris, K.
Derfalvi, B.
Hussain, I.
Haddad, E.
Dicso, F.
Darter, A.
Doralt, J.
Engl, W.
Mccoy, B.
Yel, L.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 117 (05) : S97 - S97

← 1 2 3 4 5 →